Aug 12, 2020
IDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update
May 15, 2020
IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ/11 Tumors and Preclinical MAT2A Synthetic Lethality Program
May 14, 2020
Prognostic Model Reveals High-risk Melanoma Patients that need a Clinical Trial
May 12, 2020
IDEAYA Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update
Mar 18, 2020
IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations
Mar 16, 2020
InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 as Monotherapy and Combination Therapy in Patients with Uveal Melanoma and NRAS mutant Metastatic Melanoma in the United States
Feb 25, 2020
Melanoma Research Foundation to Launch First Ever Patient-Reported Ocular Melanoma Registry
Jan 13, 2020
AmpliVox CEO Matches Donations to Eye Tumor Research Foundation In Memory of Nancy Roth
Jan 10, 2020
IDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ
Nov 20, 2019
Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress
Nov 15, 2019
Phase 1/2 Clinical Trial Progress for IDE196 to be Presented at Society for Melanoma Research Congress
Nov 13, 2019
IDEAYA Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update
Oct 31, 2019
IDEAYA Biosciences Reports End-of-Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma
Oct 08, 2019
IDEAYA Announces First Patient Dosing of IDE196 for Solid Tumors outside of Uveal Melanoma and a Collaboration with Foundation Medicine in support of its Tumor-Agnostic GNAQ/11 Basket Trial
Aug 12, 2019
IDEAYA Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
Jul 22, 2019
Research Funded by the Melanoma Research Foundation's (MRF) CURE OM Initiative Published in Nature Genetics
Jul 11, 2019
IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1/2 Tissue-Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations
May 16, 2019
Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meeting
May 08, 2019
IDEAYA Receives Authorization to Proceed with Phase 1/2 Tissue-Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ/11 Mutations and PKC Fusions
Apr 02, 2019
Arix Bioscience plc: Aura Completes $40 Million Series D Financing